Nippon Shinyaku and Eli Lilly Japan K.K have entered into an alliance agreement in Japan for pirtobrutinib, which Eli Lilly Japan is developing for Mantle cell lymphoma (MCL) and Chronic lymphocytic leukemia (CLL).

Based on this alliance agreement, Eli Lilly Japan will be responsible for the supply of pirtobrutinib after obtaining the manufacturing and marketing approval, while Nippon Shinyaku will be responsible for distribution and sales, as well as information provision activities.

In signing the alliance agreement, as Nippon Shinyaku offers several haematological cancer drugs, it is expected that the addition of pirtobrutinib to its lineup will expand the treatment options for MCL and CLL, and strengthen the haematologic oncology field.

Eli Lilly Japan by collaborating with Nippon Shinyaku, which has experience in the field of haematological cancers, will be able to contribute to the promotion of the proper use of pirtobrutinib by reliably providing information to healthcare professionals, and meet the unmet needs of more patients with MCL and CLL.

Nippon Shinyaku and Eli Lilly Japan will work closely together through the alliance agreement for pirtobrutinib to contribute to providing a new treatment option for patients with MCL and CLL in Japan.

Pirtobrutinib is a highly selective, non-covalent (reversible) inhibitor of the enzyme Bruton’s tyrosine ki- nase (BTK). BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas.